Press Release: Invetx : Invetx Completes Development of Canine and Feline Half-Life Extension Technology Platform that Significantly Extends Duration of Monoclonal Antibody Treatment Effect

BOSTON--(BUSINESS WIRE)-- #antibodytherapeuticsforanimalhealth--Invetx, a pioneer in protein-based therapeutics for animal health, announced that it has recently completed development of its species-specific, half-life extension technology for dogs and cats which leads to superior extended duration of activity for the company's veterinary monoclonal antibodies. The novel technology enables the company to optimize antibody drug treatment options for chronic, serious diseases in dogs and cats. Invetx has been granted four patents in t